AuthorsJesus G. BerdejaSarah Cannon Research Institute, Nashville, TNJesus G. Berdeja, Thomas G. Martin, Adriana Rossi, James H. Essell, David Samuel DiCapua Siegel, Sham Mailankody, Neeraj Saini, Houston Holmes, Binod Dhakal, Cristina J. Gasparetto, Samir S. Parekh, Socorro Portella, Guy Ledergor, Ashley Hammad, Franco Davi, Justin Skoble, Elizabeth Garner, Steven Brian Kanner, Syed Rizvi,…
The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.
Linda R. Duska, MD, MPH, contextualizes updated OS and PFS2 findings from the second interim analysis of KEYNOTE-A18 in locally advanced cervical cancer.
The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission,…
Experts from across oncology specialties shared some of the most talked-about abstracts and discussions from the 2025 AACR Annual Meeting.
Isabel Preeshagul, DO, MBS, discusses the need for a nuanced approach when selecting between targeted therapies in ALK- and EGFR-altered NSCLC.
The FDA granted fast track designation to emactuzumab for unresectable tenosynovial giant cell tumor.
Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.
Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.
Nerea Lopetegui-Lia, MD, discusses ongoing trials investigating ADCs that are shaking up the metastatic triple-negative breast cancer setting.
Fiona Simpkins, MD, discusses the use of cyclin E1 positivity as a biomarker of azenosertib response in platinum-resistant ovarian cancer.
